Intas Pharmaceuticals Limited Propranolol Export Data — India (DGFT 2022–2026)

Name: Intas Pharmaceuticals Limited Propranolol Export Records India — #4 Exporter, 420 Shipments, $2.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Propranolol

India Pharmaceutical Trade Intelligence

$58.1M196 Suppliers99 CountriesHS 30049074

ExportsIndia → AUSTRALIA43.9%India → UNITED STATES37.5%

ImportsUNITED STATES → India$334.4K GERMANY → India$51.5K

#1 Supplier: IPCA LABORATORIES #1 Buyer: MILPHARM LIMITED,

Intas Pharmaceuticals Limited — Propranolol Exporter #4 | $2.1M Trade Value | TransData Nexus | TransData Nexus

Intas Pharmaceuticals Limited — Propranolol Exporter Profile

Indian Pharmaceutical Exporter · #4 for Propranolol · $2.1M export value · DGFT Verified

Intas Pharmaceuticals Limited is the #4 Indian exporter of Propranolol with $2.1M in export value and 420 verified shipments. Intas Pharmaceuticals Limited holds a 3.5% market share in Propranolol exports across 5 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.

Intas Pharmaceuticals Limited — Propranolol Export Profile: Buyers & Destinations

Intas Pharmaceuticals Limited Propranolol export treemap — buyers and destination countries | TransData Nexus

Where Does Intas Pharmaceuticals Limited Export Propranolol?

Country	Value	Shipments	Share
SPAIN	$942.6K	71	44.6%
NETHERLANDS	$930.4K	131	44.0%
POLAND	$237.8K	27	11.3%
GUYANA	$1.5K	1	0.1%

Who Are the Top Buyers of Propranolol from Intas Pharmaceuticals Limited?

Buyer	Country	Value	Orders
ACCORD HEALTHCARE, SLU	SPAIN	$446.7K	42
ACCORD HEALTHCARE SLU	SPAIN	$410.9K	24
BROCACEF NL : HUB	NETHERLANDS	$387.5K	55
BROCACEF NL HUB BROCACEF HEALTHCAR	NETHERLANDS	$170.9K	13
BROCACEF NL : DUTCH	NETHERLANDS	$157.4K	38
ACCORD HEALTHCARE POLSKA SP Z O O	POLAND	$127.7K	10
BROCACEF NL HUB	NETHERLANDS	$82.2K	7
GUJARAT	SPAIN	$53.9K	3
BROCACEF NL DUTCH	NETHERLANDS	$48.0K	5
ACCORD HEALTHCARE POLSKA SP.Z.O.O.	POLAND	$41.8K	4

Intas Pharmaceuticals Limited supplies Propranolol to 21 buyers globally. The largest buyer is ACCORD HEALTHCARE, SLU (SPAIN), followed by ACCORD HEALTHCARE SLU (SPAIN) and BROCACEF NL : HUB (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Propranolol Formulations Does Intas Pharmaceuticals Limited Export?

Product Description / Formulation	Value	Shipments
PHARMA DRUGS & MEDI PROPRANOLOL 10MG 5X1	$294.4K	24
PHARMA DRUGS & MEDI PROPRANOLOL 40MG 5X1	$236.4K	30
PHARMA DRUGS & MEDI Propranolol HCl Acco	$118.2K	18
PHARMA DRUGS & MEDI PROPRANOLOL 40MG 25X	$107.7K	3
PHARMA DRUG&MED:PROPRANOLOL 10MG 5X10T(A	$96.7K	9
PHARMA DRG&MED:PROPRANOLOL 40MG 5X10T(AC	$76.3K	5
PHARMA DRG&MED:PROPRANOLOL 10MG 5X10T(AC	$68.0K	3
PHARMA DRUGS & MEDI PROPRANOLOL 10MG 5X10T(ACCORD-SPAIN AS PER INVOICE	$63.2K	3
PHARMA DRUG&MED:PROPRANOLOL 10MG 5X10TA	$63.0K	4
PHARMA DRUGS & MEDI Propranolol Accord 40 mg AS PER DOCUMENT	$59.0K	6

Intas Pharmaceuticals Limited exports 94 distinct Propranolol formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS & MEDI PROPRANOLOL 10MG 5X1 with 24 shipments worth $294.4K.

How Does Intas Pharmaceuticals Limited Compare to Nearest Propranolol Exporters?

Exporters ranked immediately above and below #4 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
3	AUROBINDO PHARMA LTD	$2.9M	103	5	$27.8K
1	IPCA LABORATORIES LIMITED	$2.8M	55	3	$50.0K
4	INTAS PHARMACEUTICALS LIMITED ★	$2.1M	420	5	$4.9K
7	WATSON PHARMA PRIVATE LIMITED	$837.6K	45	1	$18.6K
8	AUROBINDO PHARMA LIMITED	$833.6K	72	4	$11.6K

Intas Pharmaceuticals Limited ranks #4 among 196 Indian Propranolol exporters. Average shipment value of $4.9K compared to the market average of $88.4K. The closest competitors by value are AUROBINDO PHARMA LTD and IPCA LABORATORIES LIMITED.

Which Indian Ports Ship Propranolol Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	843	21.1%
DELHI AIR CARGO ACC (INDEL4)	776	19.5%
SAHAR AIR	502	12.6%
DELHI AIR	420	10.5%
NHAVA SHEVA SEA (INNSA1)	145	3.6%
MUNDRA SEA (INMUN1)	134	3.4%
Delhi Air	109	2.7%
Bombay Air	106	2.7%

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Propranolol Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)

Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Propranolol shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 442 individual customs records matching Intas Pharmaceuticals Limited exporting Propranolol, covering 94 formulations to 5 countries via 21 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 99+ countries, 363+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Propranolol

Propranolol

Intas Pharmaceuticals Limited — Propranolol Exporter Profile

Intas Pharmaceuticals Limited — Propranolol Export Profile: Buyers & Destinations

Where Does Intas Pharmaceuticals Limited Export Propranolol?

Who Are the Top Buyers of Propranolol from Intas Pharmaceuticals Limited?

What Is India's Total Propranolol Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?

What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Propranolol Exports?

How Does Intas Pharmaceuticals Limited Compare to Other Indian Propranolol Exporters?

What Propranolol Formulations Does Intas Pharmaceuticals Limited Export?

How Does Intas Pharmaceuticals Limited Compare to Nearest Propranolol Exporters?

Which Indian Ports Ship Propranolol Exports?

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Propranolol Exports

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

About Intas Pharmaceuticals Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Propranolol Export Data from Intas Pharmaceuticals Limited

Propranolol Stats

Company Overview

Top Products by Intas Pharmaceuticals Limited

Related Analysis

Need Detailed Export Data?

Data Source